Cancer News: Lung
For patients with limited metastatic non-small cell lung cancer (NSCLC), adding radiation therapy to chemotherapy with may curb disease progression dramatically.
A trial did not show a difference in overall survival (OS) between patients who received computed tomography (CT) scans as part of their follow-up, and those who did not.
Pembrolizumab – an anti PD1 therapy- is approved by FDA for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).
High-intensity interval training (HIIT) in patients with resectable non-small cell lung cancer (NSCLC) before surgey improves aerobic performance.
FDA approved atezolizumab treatment for non-small cell lung cancer (NSCLC) patients whose disease progressed during or following platinum-containing chemotherapy.
Atezolizumab, can prolong survival rate in patients with non-small-cell lung cancer regardless their PD-L1 expression.
Pembrolizumab can be the alternative option for first line treatment of patients with advanced lung cancer and high PD-L1 expression.
Hypo-fractionated radiation has similar outcomes with conventional one for non-small lung cancer patients and milder side-effects, despite its shorter duration.
Stereotactic body radiotherapy (SBRT) can improve outcomes in patients with non-small cell lung cancer (NSCLC), according to new research.
Similar quality of life for lung cancer patients with brain metastasis treated with whole brain radiotherapy compared to those who didn’t, an analysis shows.
Patients undergoing chemotherapy experienced no nausea or vomiting after including olanzapine to their prophylactic drug combination, a phase 3 study reveals.
A diagnosis of high cholesterol led to reduced mortality and improved survival in lung, breast, prostate and bowel cancer, a new researches reveals.
Merck’s Keytruda immunotherapy prolonged survival without disease progression in advanced lung cancer patients, the results of a large trial show.
Novartis's drug combination of Tafinlar and Mekinist increased progression-free survival in lung cancer patients almost up to 10 months, said the company.
A new large analysis showed that patients with stage IB non-small cell lung cancer lived longer with adjuvant chemotherapy treatment.
Patients with late-stage, non-small cell lung cancer who had surgery lived longer than those who didn’t, a new data analysis reveals.
Patients with an aggressive type of cancer called malignant pleural mesothelioma improved their quality of life after surgery, a survey reveals.
Screening patients with a high risk of developing lung cancer can identify early stage disease, improving greatly their survival rates.
Palliative care showed to improve caregivers’ quality of life and mood creating a powerful positive feedback loop in families facing cancer.
Older lung cancer patients live longer after cancer surgery, almost 2 years longer than the benchmark 5-year survival rate, a new analysis shows.
EU regulators have approved nivolumab as a treatment against advanced or metastatic non-squamous non-small cell lung cancer and advanced renal cell carcinoma.
US regulators approved crizotinib capsules for the treatment of metastatic non-small cell lung cancer.
Everolimus got approved by the FDA for the treatment of inoperable, locally advanced or metastatic neuroendocrine tumors of gastrointestinal or lung origin.
Lung and esophageal cancer survivors may not get benefit from radioactive imaging tests used to diagnose cancer recurrence, a new study reveals.
EU regulators approved osimertinib for the treatment of adult patients with a specific mutation-positive non-small cell lung cancer.
Ramucirumab received approval by the European Commission to be used as a treatment for advanced non-small cell lung cancer and metastatic colorectal cancer.
Afatinib improved progression-free survival and response in non-small cell lung cancer patients with common epidermal growth factor mutations and brain metastases.
A study comparing afatinib than gefitinib as first-line treatment in patients with advanced lung cancer showed the effectiveness of afatinib.
Afatinib appears to be more effective than gefitinib for the treatment of patients with EGFR-activating mutations in advanced lung cancer, a new study shows.
The immunotherapy drug pembrolizumab could benefit patients with refractory lung cancer selected for PD-L1 expression, a new study shows.